An independent group of advisors to the FDA overwhelmingly voted on Friday that the benefits of Intercept Pharmaceuticals' (NASDAQ:ICPT) liver disease candidate obeticholic acid (OCA) for nonalcoholic steatohepatitis (NASH) do not outweigh the risks.
https://seekingalpha.com/news/3973513-intercept-fails-fda-advisory-committee-backing-nash-drug
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.